Related Experiment Video
Updated: Aug 9, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Ticrynafen and hydrochlorothiazide in hypertension
Clinical Pharmacology and Therapeutics
|June 1, 1978
Summary
Ticrynafen effectively lowers blood pressure in patients with essential hypertension and also reduces uric acid levels. This antihypertensive medication demonstrated a favorable side effect profile compared to hydrochlorothiazide.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Essential hypertension is a prevalent cardiovascular condition requiring effective management.
- Current antihypertensive therapies may have varying effects on metabolic parameters like uric acid and electrolytes.
Purpose of the Study:
- To evaluate the efficacy and metabolic effects of ticrynafen compared to hydrochlorothiazide and placebo in patients with mild to moderate essential hypertension.
Main Methods:
- A 6-week, double-blind, randomized controlled trial involving 28 patients.
- Participants were assigned to receive ticrynafen, hydrochlorothiazide, or placebo.
Main Results:
- Both ticrynafen and hydrochlorothiazide significantly reduced blood pressure.
- Ticrynafen markedly decreased serum uric acid, while hydrochlorothiazide increased it.
- Ticrynafen showed minimal decline in serum potassium compared to hydrochlorothiazide.
- Slight increases in serum creatinine and blood urea nitrogen were observed with ticrynafen.
Conclusions:
- Ticrynafen is an effective antihypertensive agent with a notable hypouricemic effect.
- Ticrynafen presents a potentially advantageous metabolic profile for managing hypertension.
More Related Videos
Related Concept Videos
01:15Antihypertensive Drugs: Thiazide-Class Diuretics
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...